Akeso marks profit milestone with swift rights issue
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
Profit setback for Simcere Pharma in novel drugs quest
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…
FAST NEWS: Gracell shareholders approve merger with AstraZeneca
The latest: Gracell Biotechnologies Inc. (GRCL.US) announced Tuesday that its shareholders approved the company’s sale to AstraZeneca (AZN.L) at an extraordinary general meeting on Feb. 19. Looking up: Gracell’s merger with…
HighTide Therapeutics places big IPO bet on “affluenza” drug
The company is pouring almost all its R&D budget into producing a metabolic drug to treat several conditions including diabetes Key Takeaways: With no products yet on the market, HighTide…
Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
Sihuan Pharma’s Botox Beauty Bid Suffers Covid Wrinkle
The cardiovascular and cancer drug maker’s recent shift to the medical beauty business was doing well at first, but struggled last yearKey Takeaways:Sihuan Pharmaceutical’s recent move into the medical beauty…
Is Former CStone Chairman the Medicine Ailing Hengrui Needs?
Hengrui Medicine started the New Year by naming CStone’s previous top official Jiang Ningjun as its new vice general manager and chief strategy officer.Key Takeaways:Hengrui Pharma has named the former…
Recent Articles
RELATED ARTICLES
-
HBM gets health boost from drug licensing deals
2142.HK -
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
